Phibro Animal Health | PAHC - Sales Revenues


Phibro Animal Health reported $373.91M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Align Technology USD 1.04B 10M Mar/2026
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Henry Schein USD 3.37B 30M Mar/2026
Idexx Laboratories USD 1.14B 50M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Pacira USD 177M 19.87M Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Zoetis USD 2.3B 100M Mar/2026